CNS Pharmaceuticals, Inc. (CNSP) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

+75.0%

$7.68

vs $4.39 price

Levered DCF

$15.50

After debt service

Piotroski score

1 / 9

Weak

Altman Z-score

-7.36

Distress zone

Rating

C+

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-0.15×	-0.15×	-0.25×	-0.21×	-1.28×	-3.13×	-16.76×	-10.17×
P/B	0.51×	0.37×	-1.08×	0.4×	2.77×	2.07×	8.42×	-134.78×
P/S	0×	0×	0×	0×	0×	0×	0×	0×
EV / EBITDA	0.29×	0.26×	-0.24×	0.42×	-0.95×	-1.61×	-14.81×	-11.46×
Gross margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Operating margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Current ratio	1.98×	3.43×	0.26×	2.55×	3.5×	8.13×	25.38×	0.48×
Debt / equity	0.07×	0.05×	-0.07×	0.05×	0.06×	0.03×	0×	-0.58×
Interest coverage	-1,049.68×	-924.5×	-1,366.54×	-2,125.08×	-1,560.14×	-2,896.63×	-86.65×	-18.88×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-350.5%	-240.5%	425.3%	-187.8%	-218.9%	-67.8%	-51.0%	1345.7%
Return on invested capital	-329.5%	-229.2%	456.6%	-174.8%	-206.7%	-65.7%	-50.4%	379.5%
Return on assets	-183.8%	-170.8%	-1108.3%	-117.0%	-165.5%	-59.7%	-49.0%	-1081.7%
Free cash flow yield	-594.1%	-743.9%	-294.6%	-326.0%	-73.9%	-25.4%	-5.6%	-1.0%
Earnings yield	-681.0%	-645.7%	-392.7%	-471.4%	-79.1%	-32.8%	-6.1%	-10.0%
Enterprise value	-$4.5M	-$3.8M	$4.6M	-$6.4M	$13.7M	$15.2M	$56.7M	$74.1M
Net debt / EBITDA	0.43×	0.41×	0.01×	0.63×	0.32×	1.44×	1.89×	-0.01×
Cash conversion cycle (days)	0	-242,700	-514,934	-114,316	-42,527	-31,129	-54,050	0